PD-L1/pS6 in Circulating Tumor Cells (CTCs) during Osimertinib Treatment in Patients with Non-Small Cell Lung Cancer (NSCLC)Evangelia Pantazaka(University of Patras), Galatea Kallergi(University of Crete)BiomedicinesAugust 5, 202210.3390/biomedicines10081893Cited by 11SaveCiteExport RISWatch citationsRelated PapersEpithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients|Breast Cancer Research|2011|373